Company intelligence / Profile preview

Symphony Icon Holdings

Ownership: Private
Development stage: Other

Overview

Symphony Icon Holdings was established in 2007 as a product-development collaboration to accelerate development of Lexicon's early-stage serotonin synthesis inhibitors. LX1031 demonstrated positive results in Phase II trials for diarrhea-predominant and mixed forms of irritable bowel syndrome, while LX1032 was in Phase II studies for carcinoid syndrome and LX1033 was in IND-enabling studies. Lexicon reacquired all rights to these programs from Symphony Icon through restructured purchase options in 2011 and 2016[8][10].

Therapeutic areas: GastroenterologyOncology
Modalities: Small molecule
Industry: Biotech

Partnerships

Lexicon Pharmaceuticals (licensing and financing collaboration)

Beyond the preview

Go deeper on Symphony Icon Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Symphony Icon Holdings.

Explore the full profile